March 2020

Hi Jay,

Welcome to the first issue of Murrieta Genomics News. We're happy to share the most recent events and happenings with you! Feel free to reach out to us for more information or conversation.

The MG Team

Our newest company


SimplSeq is an internally developed company that we're really excited about. As the name implies, we are simplifying the NGS process - lowering costs, reducing steps, and eliminating the need for specialized technicians.

A major breakthrough is the ability for labs to retain the original DNA and RNA material - allowing for multiple assays on a single sample. This is truly revolutionary!

We believe that this will transform the industry, bringing NGS closer to patients and healthcare providers. We've been in stealth mode, but now that we have filed our initial patents and retained Perkins Coie to head our IP strategy, we are about to let the cat out of the bag!


UCR Lunch'n'Learn 

We held our first Lunch'n'Learn at UCR's Multidisciplinary Research Building (where we are a member of the wet lab incubator) and it was an outstanding success. The room was filled with scientists and entrepreneurs from UCR and we had great feedback. Our next event will be held on March 31 and your are invited to attend! Just register here.

Recent Visits

We have had many visitors to our lab over the past several months, including Microsoft, JP Morgan, Agilent, Thermo Fisher, several educational groups including those from other countries, and more. Each month we will update with our newest visitors!

Company Updates


EpigeneticsRx has made great progress since they joined the incubator. They are working with more doctors than ever before, have begun a pilot program with one of the largest healthcare providers in the country, and have expanded their team to include a genetics expert and counselor.


Tx Genetic Research is exploring the relationship between the genome and epithelial mucosa (our inner skin). This can have a tremendous impact on a number of health challenges that may affect as many as 60 million people or more in the US and that current solutions are unable to treat effectively.

Forward This Email

Do you know someone who might be interested in receiving this monthly newsletter?

Forward to a friend